GRISACTIN (griseofulvin, microcrystalline) by Thayer Medical is clinical pharmacology microbiology griseofulvin is fungistatic with in vitro activity against various species of microsporum, epidermophyton and trichophyton . Approved for the following ringworm infections. First approved in 1972.
Drug data last refreshed 1w ago
CLINICAL PHARMACOLOGY Microbiology Griseofulvin is fungistatic with in vitro activity against various species of Microsporum, Epidermophyton and Trichophyton . It has no effect on bacteria or other genera of fungi. Pharmacokinetics Following oral administration, griseofulvin is deposited in the…
Worked on GRISACTIN at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.